https://scholars.lib.ntu.edu.tw/handle/123456789/551064
標題: | Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis | 作者: | CHEN-HUA LIU Shih Y.-L Yang S.-S Lin C.-L YU-JEN FANG Cheng P.-N Chen C.-Y Peng C.-Y Hsieh T.-Y Chiu Y.-C TUNG-HUNG SU CHUN-JEN LIU HUNG-CHIH YANG PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2019 | 出版社: | Blackwell Publishing | 卷: | 34 | 期: | 11 | 起(迄)頁: | 1977-1983 | 來源出版物: | Journal of Gastroenterology and Hepatology (Australia) | 摘要: | Background and Aim: Data regarding the efficacy and safety of paritaprevir/ritonavir, ombitasvir plus dasabuvir (PrOD) for East Asian non-cirrhotic hepatitis C virus genotype 1b (HCV GT1b) patients receiving hemodialysis were limited. Methods: Forty-six HCV GT1b non-cirrhotic patients receiving hemodialysis who received PrOD for 12?weeks were prospectively enrolled in seven academic centers in Taiwan. The primary efficacy endpoint was sustained virologic response 12?weeks off-therapy (SVR12). Patients' baseline characteristics, early virokinetics, and HCV resistance-associated substitutions (RASs) potentially related to SVR12 were analyzed. The safety profiles were also assessed. Results: The SVR12 rate was 100% (46 of 46 patients). Patients' baseline characteristics, on-treatment viral decline, and baseline HCV resistance-associated substitutions did not affect SVR12. All patients tolerated treatment well. One patient with folliculitis temporarily discontinued treatment, and another two patients had serious adverse events (SAEs), which were considered not related to PrOD treatment. The common adverse events were pruritus (19.6%), fatigue (15.2%), and upper respiratory tract infection (6.5%). Twelve (19.6%) and one (2.2%) patients had hemoglobin levels 10 and 8.5?g/dL, respectively, which were related to renal impairment. Five (10.9%) patients had on-treatment total bilirubin level of 1.5–3.0?mg/dL, but none developed hepatic decompensation. The bilirubin levels peaked at week 1 of treatment and then declined with continuous treatment. Conclusion: Treatment with PrOD for 12?weeks is efficacious and well-tolerated for East Asian non-cirrhotic HCV GT1b patients receiving hemodialysis. ? 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075618669&doi=10.1111%2fjgh.14672&partnerID=40&md5=e052e55124ef6e911ad533710c56d479 https://scholars.lib.ntu.edu.tw/handle/123456789/551064 |
ISSN: | 0815-9319 | DOI: | 10.1111/jgh.14672 | SDG/關鍵字: | alanine aminotransferase; albumin; aspartate aminotransferase; bilirubin; dasabuvir; hemoglobin; interferon; ombitasvir plus paritaprevir plus ritonavir; ribavirin; virus RNA; ABT-267; ABT-450; anilide; antivirus agent; carbamic acid derivative; macrocyclic compound; ritonavir; acute gastroenteritis; adult; aged; alanine aminotransferase blood level; albumin blood level; antiviral therapy; Article; aspartate aminotransferase blood level; bilirubin blood level; clinical article; drug efficacy; drug withdrawal; East Asian; estimated glomerular filtration rate; fatigue; female; folliculitis; hemodialysis; hemoglobin blood level; hepatitis C; Hepatitis C virus subtype 1b; human; human tissue; international normalized ratio; lung edema; male; multicenter study; open study; patient compliance; platelet count; priority journal; prospective study; pruritus; side effect; sustained virologic response; treatment duration; upper respiratory tract infection; clinical trial; genetics; genotype; Hepacivirus; hepatitis C; middle aged; virology; young adult; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Middle Aged; Renal Dialysis; Ritonavir; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。